


## Apovincaminic acid hydrochloride salt

<b>Cat. No.:</b>	HY-133813A
<b>CAS No.:</b>	72296-47-0
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>23</sub> ClN <sub>2</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	358.86
<b>Target:</b>	Drug Metabolite
<b>Pathway:</b>	Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (139.33 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7866 mL	13.9330 mL	27.8660 mL
	5 mM	0.5573 mL	2.7866 mL	5.5732 mL
	10 mM	0.2787 mL	1.3933 mL	2.7866 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Apovincaminic acid hydrochloride salt is an orally active and brain-penetrant main active metabolite of Vinpocetine (VP). Apovincaminic acid hydrochloride salt exerts a neuroprotective type of action<sup>[1][2]</sup>.

#### In Vivo

Apovincaminic acid (10 mg/kg; i.p. twice daily for 4 days) effectively attenuates the behavioral deficits, and significantly decreases lesion size and the region of microglia activation<sup>[1]</sup>.

Apovincaminic acid (10 mg/kg; p.o.) is absorbed 50% of the dose comparing with i.v. administration in rats<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Harlan/Wistar rats (300-400 g) are injected NMDA <sup>[1]</sup>
Dosage:	10 mg/kg
Administration:	I.p. twice daily for 4 days
Result:	Attenuated the attention deficit effectively. Prevented the learning and memory impairment in the spontaneous alternation and

---

Morris water maze tests.  
significantly reduced lesion size microglia activation.

---

## REFERENCES

---

- [1]. Nyakas C, et, al. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. *CNS Neurosci Ther.* Summer 2009;15(2):89-99.
- [2]. Pudleiner P, et, al. Study on the absorption of vinpocetine and apovincaminic acid. *Eur J Drug Metab Pharmacokinet.* Oct-Dec 1993;18(4):317-21.
- [3]. Wang M, et, al. Simultaneous Determination of Vinpocetine and its Major Active Metabolite Apovincaminic Acid in Rats by UPLC-MS/MS and its Application to the Brain Tissue Distribution Study. *J Chromatogr Sci.* 2018 Mar 1;56(3):225-232.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA